227 episodes

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

Lung Cancer Considered IASLC

    • Science
    • 4.5 • 21 Ratings

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Genentech, Daiichi Sankyo, Inc., and Takeda

    FDA Approval: Adjuvant Alectinib for Resected NSCLC

    FDA Approval: Adjuvant Alectinib for Resected NSCLC

    In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.

    • 38 min
    IASLC DEI Initiative Global Member Survey

    IASLC DEI Initiative Global Member Survey

    As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed to help the organization better understand the challenges and areas for opportunity facing the global thoracic oncology profession. To take the survey, visit: https://www.iaslc.org/support-mission/iaslc-dei-initiative-global-member-surve

    • 27 min
    FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

    FDA Approval: FLAURA2, First Line Osimertinib Plus Chemotherapy for EGFR NSCLC

    In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

    • 47 min
    ELCC 2024 Highlights

    ELCC 2024 Highlights

    This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with Dr. Jeff Bradley, Dr. Hazel O’Sullivan, and Dr. Antonio Calles.

    • 58 min
    Emerging Agents In Small Cell Lung Cancer

    Emerging Agents In Small Cell Lung Cancer

    Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fortunately, the field continues to advance and there are several novel agents showing promise. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses some of these promising therapies with Dr. Anne Chiang and Dr. Luis Paz-Ares.

    • 41 min
    Radiopharmaceuticals and Lung Cancer

    Radiopharmaceuticals and Lung Cancer

    This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.

    • 54 min

Customer Reviews

4.5 out of 5
21 Ratings

21 Ratings

TBobo ,

Episode on Immunotherapy

Really enjoyed the conversation between these oncologist. They seem to be great doctors who really care for their patients are working for the best solutions they know of.

It was also interesting to see their blind spots. The great thing about immunotherapy is slowly opening the door between integrative oncology and traditional oncology. These guys don’t get into it but they are asking the right questions.

1) What can be combined with immunotherapy?
2) What can be done to prevent side effects of traditional treatment?
3) What things can be done to both enhance traditional treatments and lower side effects?

Naturopath and integrative doctors know many possible answer to these questions based on case studies and their personal experience. Things that will never get a $500 million dollar set of clinical trials, but have worked for patient after patient.

- Infrared Saunas to detox from chemo and have much fewer side effects (combined with other detox techniques).
- High Dose Melatonin to reduce radiation damage - with early limited clinical trials as evidence.
- Hypothermia for combining with immunotherapy.
- Proton radiation on a different schedule than normal to promote immunotherapy (3 day on 4 day off cycle seems to work better than the traditional 5 day on 2 day off, to give the immune system a chance to do its thing).
- Micro-biome research to enhance immunotherapy both through diet, supplements, and even fecal transplants.
- Natural products and off-label drugs to help limit the metabolism of cancer to slow down its growth, keep it from mutating to new food sources, and ultimately make chemo and other treatments more effective, as well as providing a much greater quality of life for the patients.

If transitional oncology would do two things, immunotherapy will advance much faster.
1) Eat a bite of humble pie and realize integrative doctors and oncologist have some answers, and start having conversations with them.
2) Realize their training and education failed them in the areas of nutrition, health, and epi-genetics.
3) Realize the level of corruption in the FDA, NIH, and pharmaceutical companies, with at least 350 MILLION dollars being passed under the table to individual for the last 10 years. This seems to be greatly hampering the rules being used to approve new drugs - creating measure that have nothing to do with patient survival - but do help big pharma profits. So after realizing there is this level of corruption and unethical behavior, it is illogical and unethical to continue to just rely on these groups to produce the “cures” for cancer.

It is going to take people doing and trying things have have more ethical motivations, writing papers, doing smaller trials, and forcing innovation solutions down the throat of the FDA with them kicking an screaming.

Then someone needs to do something to STOP the unethical price gouging of the Pharma on immunotherapy. The are obviously coordinating their pricing in a cornered market. Again unethical and unjustified. We need to vote for political leaders who can pass some laws to bring this into account.

And all the Cancer patient advocacy groups that are SILENT on these issues need to be shamed into action… even though they get big donations from big Pharma too.

DrFLC ,

Fantastic for doctors, nurses, patients

Great conversations on all things lung cancer.

yeoohaz ,

:)

great info!

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
Radiolab
WNYC Studios
Sean Carroll's Mindscape: Science, Society, Philosophy, Culture, Arts, and Ideas
Sean Carroll | Wondery
Crash Course Pods: The Universe
Crash Course Pods, Complexly
Ologies with Alie Ward
Alie Ward

You Might Also Like

Lung Cancer Update
Dr Neil Love
Plenary Session
Vinay Prasad, MD MPH
Two Onc Docs
Sam and Karine
NEJM This Week
NEJM Group
Planet Money
NPR
The Curious Clinicians
The Curious Clinicians